Luciana De Luca

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3512068/publications.pdf

Version: 2024-02-01

331670 330143 1,684 36 21 37 h-index citations g-index papers 38 38 38 3115 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	High serum levels of extracellular vesicles expressing malignancy-related markers are released in patients with various types of hematological neoplastic disorders. Tumor Biology, 2015, 36, 9739-9752.	1.8	159
2	In vivo NCL targeting affects breast cancer aggressiveness through miRNA regulation. Journal of Experimental Medicine, 2013, 210, 951-968.	8.5	121
3	Biological and Clinical Relevance of miRNA Expression Signatures in Primary Plasma Cell Leukemia. Clinical Cancer Research, 2013, 19, 3130-3142.	7.0	86
4	MiRNAs and piRNAs from bone marrow mesenchymal stem cell extracellular vesicles induce cell survival and inhibit cell differentiation of cord blood hematopoietic stem cells: a new insight in transplantation. Oncotarget, 2016, 7, 6676-6692.	1.8	86
5	MicroRNA-155 in serum-derived extracellular vesicles as a potential biomarker for hematologic malignancies - a short report. Cellular Oncology (Dordrecht), 2017, 40, 97-103.	4.4	65
6	MicroRNAs as New Biomarkers for Diagnosis and Prognosis, and as Potential Therapeutic Targets in Acute Myeloid Leukemia. International Journal of Molecular Sciences, 2018, 19, 460.	4.1	62
7	Genomeâ€wide analysis of primary plasma cell leukemia identifies recurrent imbalances associated with changes in transcriptional profiles. American Journal of Hematology, 2013, 88, 16-23.	4.1	60
8	Circulating miRNA markers show promise as new prognosticators for multiple myeloma. Leukemia, 2014, 28, 1922-1926.	7.2	55
9	Transcriptional Characterization of a Prospective Series of Primary Plasma Cell Leukemia Revealed Signatures Associated with Tumor Progression and Poorer Outcome. Clinical Cancer Research, 2013, 19, 3247-3258.	7.0	50
10	Extracellular Vesicles: A New Prospective in Crosstalk between Microenvironment and Stem Cells in Hematological Malignancies. Stem Cells International, 2018, 2018, 1-11.	2.5	47
11	Characterization and prognostic relevance of circulating microvesicles in chronic lymphocytic leukemia. Leukemia and Lymphoma, 2017, 58, 1424-1432.	1.3	43
12	Clinical relevance of extracellular vesicles in hematological neoplasms: from liquid biopsy to cell biopsy. Leukemia, 2021, 35, 661-678.	7.2	40
13	MicroRNAs: New Players in Multiple Myeloma. Frontiers in Genetics, 2011, 2, 22.	2.3	37
14	Mesenchymal Stem Cell Derived Extracellular Vesicles: A Role in Hematopoietic Transplantation?. International Journal of Molecular Sciences, 2017, 18, 1022.	4.1	36
15	Knockdown of miR-128a induces Lin28a expression and reverts myeloid differentiation blockage in acute myeloid leukemia. Cell Death and Disease, 2017, 8, e2849-e2849.	6.3	32
16	Extracellular Vesicles in Hematological Malignancies: From Biology to Therapy. International Journal of Molecular Sciences, 2017, 18, 1183.	4.1	31
17	Targeting the p53-MDM2 interaction by the small-molecule MDM2 antagonist Nutlin-3a: a new challenged target therapy in adult Philadelphia positive acute lymphoblastic leukemia patients. Oncotarget, 2016, 7, 12951-12961.	1.8	28
18	P53-MDM2 Pathway: Evidences for A New Targeted Therapeutic Approach in B-Acute Lymphoblastic Leukemia. Frontiers in Pharmacology, 2016, 7, 491.	3.5	27

#	Article	IF	Citations
19	Molecular Classification and Pharmacogenetics of Primary Plasma Cell Leukemia: An Initial Approach toward Precision Medicine. International Journal of Molecular Sciences, 2015, 16, 17514-17534.	4.1	23
20	Epha3 acts as proangiogenic factor in multiple myeloma. Oncotarget, 2017, 8, 34298-34309.	1.8	23
21	An update on extracellular vesicles in multiple myeloma: a focus on their role in cell-to-cell cross-talk and as potential liquid biopsy biomarkers. Expert Review of Molecular Diagnostics, 2019, 19, 249-258.	3.1	20
22	A Pyrazolo $[3,4-\langle i\rangle d\langle i\rangle]$ pyrimidine compound inhibits Fyn phosphorylation and induces apoptosis in natural killer cell leukemia. Oncotarget, 2016, 7, 65171-65184.	1.8	18
23	Aberrant activation of ROS1 represents a new molecular defect in chronic myelomonocytic leukemia. Leukemia Research, 2013, 37, 520-530.	0.8	17
24	Future in the Past: Azorella glabra Wedd. as a Source of New Natural Compounds with Antiproliferative and Cytotoxic Activity on Multiple Myeloma Cells. International Journal of Molecular Sciences, 2018, 19, 3348.	4.1	17
25	EphA3 targeting reduces in vitro adhesion and invasion and in vivo growth and angiogenesis of multiple myeloma cells. Cellular Oncology (Dordrecht), 2017, 40, 483-496.	4.4	15
26	Analysis of Amount, Size, Protein Phenotype and Molecular Content of Circulating Extracellular Vesicles Identifies New Biomarkers in Multiple Myeloma. International Journal of Nanomedicine, 2021, Volume 16, 3141-3160.	6.7	14
27	DNA methylation dynamic of bone marrow hematopoietic stem cells after allogeneic transplantation. Stem Cell Research and Therapy, 2019, 10, 138.	5.5	12
28	A Pyrazolo[3,4-d]pyrimidine Compound Reduces Cell Viability and Induces Apoptosis in Different Hematological Malignancies. Frontiers in Pharmacology, 2016, 7, 416.	3.5	8
29	Multiple Myeloma-Derived Extracellular Vesicles Impair Normal Hematopoiesis by Acting on Hematopoietic Stem and Progenitor Cells. Frontiers in Medicine, 2021, 8, 793040.	2.6	7
30	Deferasirox drives ROS-mediated differentiation and induces interferon-stimulated gene expression in human healthy haematopoietic stem/progenitor cells and in leukemia cells. Stem Cell Research and Therapy, 2019, 10, 171.	5.5	5
31	Acute Myeloid Leukemia Cells Functionally Compromise Hematopoietic Stem/Progenitor Cells Inhibiting Normal Hematopoiesis Through the Release of Extracellular Vesicles. Frontiers in Oncology, 2022, 12, 824562.	2.8	5
32	Advances in Azorella glabra Wedd. Extract Research: In Vitro Antioxidant Activity, Antiproliferative Effects on Acute Myeloid Leukemia Cells and Bioactive Compound Characterization. Molecules, 2020, 25, 4890.	3.8	4
33	Dissecting chronic lymphocytic leukemia with 13q- using microRNA expression profile. Leukemia Research, 2016, 47, 114-115.	0.8	3
34	Inverse regulation of bridging integrator 1 and BCR-ABL1 in chronic myeloid leukemia. Tumor Biology, 2016, 37, 217-225.	1.8	2
35	A case of acute promyelocytic leukemia variant with derivative chromosome 3 der(3)t(3;8) associated with 8q partial gain. Molecular Cytogenetics, 2019, 12, 32.	0.9	1
36	In vivo NCL targeting affects breast cancer aggressiveness through miRNA regulation. Journal of Cell Biology, 2013, 201, i4-i4.	5.2	0